Related Experiment Video
Updated: May 14, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging
Published on: June 8, 2017
Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria
Abstract:
Cerebral malaria (CM) due to Plasmodium falciparum ( Pf ) infection is a major cause of death in African children. Bradykinin (BK) is a mediator of vasogenic edema. It could contribute to the pathogenesis of central nervous system malaria in Kenyan children and P. berghei ANKA ( PbA ) infected C57BL/6J mice with experimental cerebral malaria. Cleaved plasma high molecular weight kininogen (cHK) is a marker for prior BK release. 40% of children with central nervous system malaria had plasma cHK versus 18% of children with uncomplicated malaria. Wild-type PbA -infected mice had circulating plasma cHK, elevated BK levels, and reduced HK and prekallikrein levels. HK null ( Kng1 -/- ), combined BK B1 and B2 receptor null ( Bdkrb1 -/- / Bdkrb2 -/- ), BK B2 ( Bdkrb2 -/- ) or BK B1 ( Bdkrb1 -/- ) receptor null mice were protected from neurologic deterioration and brain edema compared to wild-type mice. F12 -/- mice were not protected from neurological deterioration. Prekallikrein null ( Klkb1 -/- ), prolylcarboxypeptidase hypomorphs ( Prcp gt/gt ), and brain endothelial cell conditional knockout of PRCP ( Prcp fl/fl Cre) mice had reduced neurologic deterioration and brain edema. Adjuvant plasma kallikrein inhibition combined with artesunate treatment of PbA -infected mice reversed neurologic deterioration and brain edema and prolonged survival relative to artesunate alone. BK-induced vasogenic edema contributes to human and murine CM.
Insights
Bradykinin (BK) contributes to brain swelling and neurological damage in cerebral malaria (CM). Blocking BK pathways or inhibiting plasma kallikrein reduces CM severity and improves survival in mouse models, suggesting new therapeutic targets.
Area of Science:
- Neuroscience
- Immunology
- Parasitology
Background:
- Cerebral malaria (CM), caused by *Plasmodium falciparum*, is a leading cause of death in African children.
- Bradykinin (BK) is implicated in vasogenic edema and may contribute to CM pathogenesis.
- Cleaved high molecular weight kininogen (cHK) serves as a biomarker for BK release.
Purpose of the Study:
- To investigate the role of the bradykinin system in the pathogenesis of cerebral malaria.
- To evaluate the therapeutic potential of targeting BK pathways in experimental CM.
Main Methods:
- Analysis of plasma cHK levels in children with CM and uncomplicated malaria.
- Studies in wild-type and genetically modified mice (*Kng1* null, BK receptor null, *Klkb1* null, *Prcp* hypomorph/conditional knockout) infected with *P. berghei* ANKA (PbA).
- Assessment of neurological deterioration, brain edema, and survival.
- Evaluation of combined artesunate and plasma kallikrein inhibition treatment in PbA-infected mice.
Main Results:
- Elevated plasma cHK levels were observed in children and PbA-infected mice with CM.
- Mice lacking functional components of the BK system (receptors, kininogen, prekallikrein, prolylcarboxypeptidase) showed protection against CM.
- Combined inhibition of plasma kallikrein with artesunate reversed neurological deficits and brain edema, prolonging survival in mice.
Conclusions:
- Bradykinin-induced vasogenic edema is a significant contributor to the pathophysiology of both human and murine cerebral malaria.
- Targeting the bradykinin system, particularly plasma kallikrein, represents a promising therapeutic strategy for CM.
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Cerebral Edema l: Introduction
Cytotoxic Edema: Pathophysiology
Bacterial Meningitis II: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology

